Prophylactic Antibiotic in Treatment of Fingertip Amputation

NCT ID: NCT02077400

Last Updated: 2015-07-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fingertip amputation is a common injury. Considerable controversy exists as to whether prophylactic antibiotics are necessary for this injury. The investigators goal was to compare the rate of infections among subgroups with and without prophylactic antibiotic treatment. The study hypothesis was that infection rates were similar in the two groups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infection Rate After Fingertip Amputation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

no antibiotic

Group Type NO_INTERVENTION

No interventions assigned to this group

Cephazolin

cefazoline

Group Type ACTIVE_COMPARATOR

Cephazolin

Intervention Type DRUG

Cephazolin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cephazolin

Cephazolin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cefamezine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* fingertip amputation with bone exposed

Exclusion Criteria

* under the age of 18 years
* if the patient had diabetes
* oncological disorder
* immune deficiency
* bleeding disorder
* used steroids regularly
* presented with a grossly contaminated wound or other injury requiring antibiotic treatment
* were currently taking antibiotics, or had a previous allergic reaction to cephalosporins.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

HaEmek Medical Center, Israel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

guy rubin

Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HaEmek medical center

Afula, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0115-09-EMC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Antibiotic Prophylaxis in Pediatric Open Fractures
NCT06055712 ENROLLING_BY_INVITATION PHASE4
Or v IV Antibiotics for Infection
NCT04723940 UNKNOWN PHASE3
Antibiotics in Free Flaps Reconstructions
NCT02436083 COMPLETED PHASE4
Local Antibiotics for Breast Implants
NCT04731025 RECRUITING PHASE3